Sakakibara, Fumihiro
Ueda, Shinichiro
Uchida, Kazutaka
Kinjo, Norito
Arai, Hideki
Nezu, Mari
Morimoto, Takeshi
Article History
Received: 25 September 2021
Revised: 14 December 2021
Accepted: 4 January 2022
First Online: 17 February 2022
Compliance with ethical standards
:
: FS reports paper fees from Medicus Shuppan. SU reports receiving research grants from Bristol-Myers Squibb, Chugai, Kowa, MSD, Pfizer, and Takeda, lecturer fees from Boehringer Ingelheim, MSD, and Taiho, and paper fees from Kowa. He served on an advisory board for Otsuka. KU reports receiving lecturer fees from Daiichi Sankyo, Bristol-Myers Squibb, Stryker, and Medtronic. NK reports receiving lecturer fees from Medtronic and paper fees from Medicus Shuppan. HA and MN have no disclosures to report. TM reports receiving lecturer fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray, receiving paper fees from Bristol-Myers Squibb and Kowa, and served on an advisory board for Sanofi.
: The institutional review boards of the University of the Ryukyus (No. 597) and all 71 participating centers approved the study protocol. The institutional review boards waived the need for written informed consent and approved the study following the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.